d)BRAF/MEK Inhibitors with Immunotherapy: In melanoma cases with BRAF mutations, targeted therapy with BRAF and MEK inhibitors is combined with immunotherapy to maximize treatment response. The gene discussed is MAP2K7; the disease is melanoma.